{"id":"nivolumab-and-ipilimumab","_chembl":null,"_fixedAt":"2026-03-30T11:30:10.267325","_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=nivolumab-and-ipilimumab","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-19T23:49:38.922401+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-19T23:49:45.306523+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=nivolumab-and-ipilimumab","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T23:49:46.088915+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Cytotoxic T-lymphocyte protein 4 inhibitor","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:49:47.209520+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1789844/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:49:47.112946+00:00"}},"allNames":"nivolumab and ipilimumab","_dailymed":null,"mechanism":{"target":"PD-1, CTLA-4","drugClass":"PD-1 inhibitor, CTLA-4 inhibitor","explanation":"Nivolumab blocks the PD-1 receptor, while ipilimumab inhibits CTLA-4, both of which help to activate T-cells and boost the immune system's ability to fight cancer.","oneSentence":"Nivolumab and ipilimumab work by targeting PD-1 and CTLA-4 receptors, enhancing T-cell activation and immune response against cancer cells."},"_scrapedAt":"2026-03-27T23:28:28.659Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"commercial":{"revenueYear":2025,"annualRevenue":2900,"revenueSource":"SEC 8-K Bristol-Myers Squibb (2026-02-05)","revenueCurrency":"USD","revenueConfidence":"verified (SEC filing)","revenueExtractedAt":"2026-04-01T11:46:55.105249","revenueExtractedBy":"revenue-sec"},"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:49:49.023726+00:00","fieldsConflicting":0,"overallConfidence":0.95},"_fixedFields":["modality→Monoclonal Antibody"],"trialDetails":[{"nctId":"NCT01896999","phase":"PHASE1, PHASE2","title":"Brentuximab Vedotin and Nivolumab With or Without Ipilimumab in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2014-03-07","conditions":"Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma","enrollment":146},{"nctId":"NCT05112601","phase":"PHASE2","title":"Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-06-02","conditions":"Endometrial Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Dedifferentiated Carcinoma","enrollment":81},{"nctId":"NCT04317105","phase":"PHASE1, PHASE2","title":"Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without Ipilimumab) in Patients With Advanced Solid Cancers That Have Changes in the Following Genes: PIK3CA and PTEN","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-07-17","conditions":"Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm","enrollment":54},{"nctId":"NCT02496208","phase":"PHASE1","title":"Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2015-07-22","conditions":"Bladder Small Cell Neuroendocrine Carcinoma, Bladder Squamous Cell Carcinoma, Bladder Urothelial Carcinoma","enrollment":152},{"nctId":"NCT02834013","phase":"PHASE2","title":"Nivolumab and Ipilimumab in Treating Patients With Rare Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2017-01-30","conditions":"Acinar Cell Carcinoma, Adenoid Cystic Carcinoma, Adrenal Cortical Carcinoma","enrollment":818},{"nctId":"NCT04840589","phase":"PHASE1","title":"Testing the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid Tumors","status":"SUSPENDED","sponsor":"National Cancer Institute (NCI)","startDate":"2022-02-02","conditions":"Metastatic Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm, Recurrent Platinum-Resistant Ovarian Carcinoma","enrollment":66},{"nctId":"NCT05896839","phase":"PHASE1, PHASE2","title":"Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-07-24","conditions":"Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8","enrollment":16},{"nctId":"NCT04145115","phase":"PHASE2","title":"A Study Testing the Effect of Immunotherapy (Ipilimumab and Nivolumab) in Patients With Recurrent Glioma With Elevated Mutational Burden","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-12-24","conditions":"Astrocytoma, IDH-Mutant, Grade 4, Diffuse Glioma, Glioblastoma, IDH-Wildtype","enrollment":37},{"nctId":"NCT03816358","phase":"PHASE1","title":"Testing the Combination of Anetumab Ravtansine With Either Nivolumab, Nivolumab and Ipilimumab, or Gemcitabine and Nivolumab in Advanced Pancreatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-12-09","conditions":"Pancreatic Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8","enrollment":74},{"nctId":"NCT03546686","phase":"PHASE2","title":"Peri-Operative Immune Checkpoint Inhibition and Cryoablation in Women With Triple-negative Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Texas Southwestern Medical Center","startDate":"2019-11-12","conditions":"Breast Cancer","enrollment":51},{"nctId":"NCT03297606","phase":"PHASE2","title":"Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)","status":"RECRUITING","sponsor":"Canadian Cancer Trials Group","startDate":"2018-03-23","conditions":"Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid Tumors","enrollment":720},{"nctId":"NCT03502733","phase":"PHASE1","title":"Testing the Combination of Copanlisib, Nivolumab and Ipilimumab in Patients With Advanced Cancer and Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2018-08-14","conditions":"Lymphoma, Metastatic Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm","enrollment":64},{"nctId":"NCT03793166","phase":"PHASE3","title":"Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-06-07","conditions":"Clear Cell Renal Cell Carcinoma, Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Neoplasm in the Lymph Nodes","enrollment":1175},{"nctId":"NCT05904080","phase":"PHASE2","title":"Testing Nivolumab and Ipilimumab Immunotherapy With or Without the Targeted Drug Cabozantinib in Recurrent, Metastatic, or Incurable Nasopharyngeal Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-02-19","conditions":"Metastatic Nasopharyngeal Carcinoma, Recurrent Nasopharyngeal Carcinoma, Stage IV Nasopharyngeal Carcinoma AJCC v8","enrollment":50},{"nctId":"NCT04751370","phase":"PHASE2","title":"Testing Nivolumab and Ipilimumab With Short-Course Radiation in Locally Advanced Rectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-02-08","conditions":"Locally Advanced Rectal Adenocarcinoma, Stage II Rectal Cancer AJCC v8, Stage III Rectal Cancer AJCC v8","enrollment":31},{"nctId":"NCT03604991","phase":"PHASE2, PHASE3","title":"Nivolumab and Ipilimumab in Treating Patients With Esophageal and Gastroesophageal Junction Adenocarcinoma Undergoing Surgery","status":"SUSPENDED","sponsor":"National Cancer Institute (NCI)","startDate":"2019-05-03","conditions":"Clinical Stage II Esophageal Adenocarcinoma AJCC v8, Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage III Esophageal Adenocarcinoma AJCC v8","enrollment":278},{"nctId":"NCT03866382","phase":"PHASE2","title":"Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-05-13","conditions":"Bladder Adenocarcinoma, Bladder Clear Cell Adenocarcinoma, Bladder Mixed Adenocarcinoma","enrollment":314},{"nctId":"NCT02339571","phase":"PHASE2, PHASE3","title":"A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2015-11-23","conditions":"Stage III Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7","enrollment":600},{"nctId":"NCT03604978","phase":"PHASE1, PHASE2","title":"Nivolumab and Multi-fraction Stereotactic Radiosurgery With or Without Ipilimumab in Treating Patients With Recurrent Grade II-III Meningioma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-06-17","conditions":"Grade 2 Meningioma, Grade 3 Meningioma, Recurrent Meningioma","enrollment":38},{"nctId":"NCT04929041","phase":"PHASE2, PHASE3","title":"Testing the Addition of Radiation Therapy to the Usual Treatment (Immunotherapy With or Without Chemotherapy) for Advanced Stage Non-small Cell Lung Cancer Patients Who Are PD-L1 Negative","status":"SUSPENDED","sponsor":"National Cancer Institute (NCI)","startDate":"2022-10-07","conditions":"Lung Adenocarcinoma, Lung Adenosquamous Carcinoma, Lung Non-Small Cell Carcinoma","enrollment":427},{"nctId":"NCT03017820","phase":"PHASE1","title":"A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2017-04-04","conditions":"B-Cell Non-Hodgkin Lymphoma, Histiocytic and Dendritic Cell Neoplasm, Myelodysplastic Syndrome","enrollment":127},{"nctId":"NCT02453620","phase":"PHASE1","title":"Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2016-02-12","conditions":"Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Breast Adenocarcinoma","enrollment":57},{"nctId":"NCT03914300","phase":"PHASE2","title":"Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-02-10","conditions":"Differentiated Thyroid Gland Carcinoma, Follicular Variant Thyroid Gland Papillary Carcinoma, Poorly Differentiated Thyroid Gland Carcinoma","enrollment":11},{"nctId":"NCT04079712","phase":"PHASE2","title":"Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-08-06","conditions":"Metastatic Large Cell Neuroendocrine Carcinoma, Metastatic Neuroendocrine Carcinoma, Metastatic Neuroendocrine Neoplasm","enrollment":17},{"nctId":"NCT06946797","phase":"PHASE2","title":"A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)","status":"RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2025-09-19","conditions":"Non-Small Cell Lung Cancer","enrollment":76},{"nctId":"NCT07174947","phase":"PHASE2","title":"SSRI Antidepressant Fluoxetine Improving Immunotherapy Efficacy in Advanced Hepatobiliary Malignancy Patients With Depression and Anxiety","status":"RECRUITING","sponsor":"First Affiliated Hospital of Wenzhou Medical University","startDate":"2025-10-01","conditions":"Hepatobiliary Malignancy, Fluoxetine, Anxiety Disorders","enrollment":240},{"nctId":"NCT03899155","phase":"PHASE2","title":"Pan Tumor Rollover Study","status":"RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2019-08-09","conditions":"Cancer","enrollment":1500},{"nctId":"NCT03391869","phase":"PHASE3","title":"Nivolumab and Ipilimumab With or Without Local Consolidation Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2017-12-29","conditions":"Lung Adenocarcinoma, Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8","enrollment":339},{"nctId":"NCT04462406","phase":"PHASE2","title":"Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2021-02-09","conditions":"Advanced Melanoma, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8","enrollment":150},{"nctId":"NCT05700461","phase":"PHASE1","title":"Drug Screening Using Novel IMD in Renal Cell Carcinoma","status":"ENROLLING_BY_INVITATION","sponsor":"Oliver Jonas","startDate":"2024-12-01","conditions":"Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma, Kidney Cancer","enrollment":20},{"nctId":"NCT03521830","phase":"PHASE2","title":"Nivolumab Alone or Plus Relatlimab or Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell Carcinoma","status":"RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2018-11-27","conditions":"Basal Cell Carcinoma","enrollment":57},{"nctId":"NCT07401875","phase":"PHASE1","title":"A Phase 1b Study of HC-7366, an Agonist of ISR With Immunotherapy in Kidney Cancer (SHARK)","status":"NOT_YET_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2026-07-28","conditions":"Phase 1b, HC-7366, SHARK","enrollment":35},{"nctId":"NCT07482059","phase":"PHASE1, PHASE2","title":"A Multicenter Clinical Study of Combined Therapy for Unresectable Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"West China Hospital","startDate":"2026-02","conditions":"Unresectable Hepatocellular Carcinoma","enrollment":33},{"nctId":"NCT02693535","phase":"PHASE2","title":"TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer","status":"RECRUITING","sponsor":"American Society of Clinical Oncology","startDate":"2016-03-14","conditions":"Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid Tumors","enrollment":4200},{"nctId":"NCT06743126","phase":"PHASE3","title":"SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma","status":"RECRUITING","sponsor":"Immatics US, Inc.","startDate":"2025-01-14","conditions":"Melanoma, Cutaneous Malignant","enrollment":360},{"nctId":"NCT04817254","phase":"PHASE2","title":"Association of Peripheral Blood Immunologic Response to Therapeutic Response to Adjuvant Treatment With Immune Checkpoint Inhibition (ICI) in Patients With Newly Diagnosed Glioblastoma or Gliosarcoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-12-08","conditions":"Glioblastoma, Gliosarcoma, Malignant Glioma","enrollment":47},{"nctId":"NCT03799445","phase":"PHASE2","title":"Ipilimumab, Nivolumab, and Radiation Therapy in Treating Patients With HPV Positive Advanced Oropharyngeal Squamous Cell Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2019-07-25","conditions":"Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Human Papillomavirus Positive Oropharyngeal Squamous Cell Carcinoma","enrollment":37},{"nctId":"NCT07176650","phase":"PHASE1","title":"Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"Shanghai Henlius Biotech","startDate":"2025-11-25","conditions":"Hepatocellular Carcinoma (HCC)","enrollment":246},{"nctId":"NCT03945773","phase":"PHASE2","title":"Study of Cabozantinib as 2nd Line Treatment in Subjects With Locally Advanced or Metastatic Renal Cell Carcinoma (RCC) With a Clear-Cell Component Who Progressed After 1st Line Treatment With Checkpoint Inhibitors","status":"COMPLETED","sponsor":"Ipsen","startDate":"2020-01-08","conditions":"Locally Advanced or Metastatic Renal Cell Carcinoma","enrollment":127},{"nctId":"NCT06708949","phase":"PHASE2","title":"A Randomized Phase 2 Trial of Nivolumab, Relatlimab Plus Ipilimumab vs. Nivolumab Plus Ipilimumab in First-line Advanced Renal Cell Carcinoma (RCC)","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2025-03-20","conditions":"Renal Cell Carcinoma, Clear Cell","enrollment":15},{"nctId":"NCT05176483","phase":"PHASE1","title":"Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors","status":"RECRUITING","sponsor":"Exelixis","startDate":"2021-12-14","conditions":"Renal Cell Carcinoma (RCC), Metastatic Castration-Resistant Prostate Cancer (mCRPC), Urothelial Carcinoma (UC)","enrollment":1314},{"nctId":"NCT03071406","phase":"PHASE2","title":"Randomized Study of Nivolumab+Ipilimumab+/- SBRT for Metastatic Merkel Cell Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2017-03-14","conditions":"Merkel Cell Carcinoma, Skin Cancer","enrollment":50},{"nctId":"NCT04697576","phase":"PHASE1","title":"Intralesional Influenza Vaccine for the Treatment of Stage I-IV Melanoma","status":"RECRUITING","sponsor":"Carlo Contreras","startDate":"2021-10-20","conditions":"Clinical Stage I Cutaneous Melanoma AJCC v8, Clinical Stage IA Cutaneous Melanoma AJCC v8, Clinical Stage IB Cutaneous Melanoma AJCC v8","enrollment":36},{"nctId":"NCT07000149","phase":"PHASE3","title":"A Study to Investigate the Efficacy and Safety of Volrustomig ± Casdatifan vs Nivolumab + Ipilimumab as 1L Treatment for Advanced ccRCC","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2025-07-28","conditions":"Advanced Clear Cell Renal Cell Carcinoma","enrollment":1116},{"nctId":"NCT05926960","phase":"PHASE2","title":"A Study Comparing 3 Study Medicines (Encorafenib, Binimetinib, Pembrolizumab) to 2 Study Medicines (Ipilimumab and Nivolumab) in Patients With Advanced Melanoma","status":"TERMINATED","sponsor":"Pfizer","startDate":"2023-06-13","conditions":"Melanoma","enrollment":38},{"nctId":"NCT03999749","phase":"PHASE2","title":"A Phase II Study of the Interleukin-6 Receptor Inhibitor Tocilizumab in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"NYU Langone Health","startDate":"2019-06-11","conditions":"Melanoma","enrollment":71},{"nctId":"NCT04940299","phase":"PHASE2","title":"Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-09-23","conditions":"Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Locally Advanced Bladder Carcinoma","enrollment":35},{"nctId":"NCT03036098","phase":"PHASE3","title":"Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Participants With Untreated Inoperable or Metastatic Urothelial Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2017-03-24","conditions":"Urothelial Cancer","enrollment":1314},{"nctId":"NCT04013542","phase":"PHASE1","title":"Ipilimumab and Nivolumab in Combination With Radiation Therapy in Treating Patients With Stage 2-3 Non-small Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2019-09-13","conditions":"ALK Gene Rearrangement, EGFR Gene Mutation, Locally Advanced Lung Non-Small Cell Carcinoma","enrollment":21},{"nctId":"NCT04396860","phase":"PHASE2, PHASE3","title":"Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2020-09-01","conditions":"Gliosarcoma, MGMT-Unmethylated Glioblastoma","enrollment":159},{"nctId":"NCT02530463","phase":"PHASE2","title":"Nivolumab and/or Ipilimumab With or Without Azacitidine in Treating Patients With Myelodysplastic Syndrome","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2015-09-08","conditions":"Leukemia, Myelodysplastic Syndrome, Recurrent Myelodysplastic Syndrome","enrollment":99},{"nctId":"NCT03026140","phase":"PHASE2","title":"Neoadjuvant Immune Checkpoint Inhibition and Novel IO Combinations in Early-stage Colon Cancer","status":"RECRUITING","sponsor":"The Netherlands Cancer Institute","startDate":"2017-03-29","conditions":"Colon Carcinoma","enrollment":353},{"nctId":"NCT03307616","phase":"PHASE2","title":"Nivolumab With and Without Ipilimumab and Radiation Therapy in Treating Patients With Recurrent or Resectable Undifferentiated Pleomorphic Sarcoma or Dedifferentiated Liposarcoma Before Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2017-10-04","conditions":"Dedifferentiated Liposarcoma, Recurrent Dedifferentiated Liposarcoma, Recurrent Undifferentiated Pleomorphic Sarcoma","enrollment":32},{"nctId":"NCT07293351","phase":"PHASE1, PHASE2","title":"A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Ipilimumab or Cabozantinib in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)","status":"RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2026-03-26","conditions":"Advanced Renal Cell Carcinoma (RCC)","enrollment":234},{"nctId":"NCT03223155","phase":"PHASE1","title":"Concurrent or Sequential Immunotherapy and Radiation Therapy in Patients With Metastatic Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Chicago","startDate":"2017-09-07","conditions":"Stage IV Small Cell Lung Cancer","enrollment":78},{"nctId":"NCT06097728","phase":"PHASE3","title":"MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2023-11-09","conditions":"Unresectable Pleural Mesothelioma","enrollment":825},{"nctId":"NCT05647265","phase":"PHASE2","title":"Testing the Addition of Immunotherapy Before Surgery for Patients With Sarcomatoid Mesothelioma","status":"RECRUITING","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2024-11-27","conditions":"Pleural Biphasic Mesothelioma, Pleural Sarcomatoid Mesothelioma","enrollment":26},{"nctId":"NCT04091750","phase":"PHASE2","title":"Nivolumab/Ipilimumab Plus Cabozantinib in Patients With Unresectable Advanced Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Georgetown University","startDate":"2020-03-02","conditions":"Melanoma","enrollment":14},{"nctId":"NCT07444619","phase":"PHASE1","title":"A Phase I Study of Pazopanib in Combination With Trabectedin, Ipilimumab and Nivolumab (TraPIN) in Pediatric and Young Adult Patients With Recurrent Soft Tissue Sarcomas","status":"NOT_YET_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2026-08-31","conditions":"Soft Tissue Sarcomas","enrollment":18},{"nctId":"NCT06047379","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis","status":"RECRUITING","sponsor":"Neonc Technologies, Inc.","startDate":"2023-11-01","conditions":"Diffuse Astrocytoma, IDH-Mutant, Glioblastoma, IDH-wildtype, Brain Metastases, Adult","enrollment":134},{"nctId":"NCT07436390","phase":"NA","title":"IFN-Gamma Expression as a Predictor of Response to Immune Checkpoint Inhibitors in First-Line Metastatic Melanoma","status":"COMPLETED","sponsor":"Institute of Oncology Ljubljana","startDate":"2024-03-31","conditions":"Metastatic Melanoma, Malignant Melanoma, Skin Cancer","enrollment":132},{"nctId":"NCT05048212","phase":"PHASE2","title":"A Phase II Study of Nivolumab With Ipilimumab and Cabozantinib in Patients With Untreated Renal Cell Carcinoma Brain Metastases","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2022-09-20","conditions":"Brain Metastases, Renal Cell Carcinoma","enrollment":20},{"nctId":"NCT04969887","phase":"PHASE2","title":"Combination Immunotherapy in Rare Cancers Under InvesTigation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Olivia Newton-John Cancer Research Institute","startDate":"2021-08-03","conditions":"Advanced Biliary Tract Cancer, Neuroendocrine Tumors, Female Reproductive System Neoplasm","enrollment":240},{"nctId":"NCT03564197","phase":"NA","title":"18F-PD-L1 PET/CT in Nivolumab Treated Patients With NSCLC","status":"COMPLETED","sponsor":"The Netherlands Cancer Institute","startDate":"2018-10-25","conditions":"NSCLC Stage IV","enrollment":80},{"nctId":"NCT07128680","phase":"PHASE1","title":"Immunotherapy (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic Product (EXL01) for the Treatment of Metastatic Renal Cell Cancer","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2026-04-01","conditions":"Advanced Clear Cell Renal Cell Carcinoma, Advanced Sarcomatoid Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma","enrollment":33},{"nctId":"NCT07428252","phase":"NA","title":"Gastrointestinal Microbiome and Response to Immunotherapy in Metastatic Malignant Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Institute of Oncology Ljubljana","startDate":"2022-03-01","conditions":"Metastatic Malignant Melanoma","enrollment":150},{"nctId":"NCT07430202","phase":"PHASE1","title":"A DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Glutamine Antagonist DRP-104, Nivolumab, and Ipilimumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)","status":"NOT_YET_RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2026-05","conditions":"Liver Cancer (Fibrolamellar Hepatocellular Cancer (FLC))","enrollment":27},{"nctId":"NCT06587451","phase":"PHASE3","title":"Integrated Pharmacokinetics (PK)/Efficacy, Safety, and Immunogenicity Study to Demonstrate Similarity of JPB898, a Proposed Biosimilar to Nivolumab, to Opdivo® in Combination With Yervoy®","status":"TERMINATED","sponsor":"Sandoz","startDate":"2024-12-19","conditions":"Melanoma","enrollment":52},{"nctId":"NCT03400332","phase":"PHASE1, PHASE2","title":"A Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced Cancers","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2018-02-12","conditions":"Cancer, Melanoma","enrollment":281},{"nctId":"NCT07188896","phase":"PHASE2","title":"A Randomized Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC)","status":"RECRUITING","sponsor":"Brian Rini","startDate":"2026-03","conditions":"Advanced Renal Cell Carcinoma (aRCC), Metastatic Renal Cell Carcinoma ( mRCC), Clear Cell Renal Cell Carcinoma (ccRCC)","enrollment":120},{"nctId":"NCT07422779","phase":"NA","title":"Immunotherapy Efficacy and PD-L1 as a Predictive Biomarker in Metastatic Melanoma in Slovenia","status":"RECRUITING","sponsor":"Institute of Oncology Ljubljana","startDate":"2022-03-01","conditions":"Metastatic Melanoma, Skin Cancer","enrollment":100},{"nctId":"NCT06999980","phase":"PHASE2","title":"Neo IRENIE (NEOadjuvant Ipilimumab, RElatlimab, NIvolumab Evaluation)","status":"RECRUITING","sponsor":"Melanoma Institute Australia","startDate":"2026-02-09","conditions":"Cutaneous Melanoma, Mucosal Melanoma","enrollment":494},{"nctId":"NCT04039607","phase":"PHASE3","title":"A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2019-09-30","conditions":"Hepatocellular Carcinoma","enrollment":732},{"nctId":"NCT06524570","phase":"PHASE1","title":"Treatment of Cancer With Immune Checkpoint Inhibition Therapy Boosted by High Intensity Focused Ultrasound Histotripsy","status":"RECRUITING","sponsor":"UMC Utrecht","startDate":"2024-07-26","conditions":"Cancer, Metastatic Cancer","enrollment":24},{"nctId":"NCT05384496","phase":"PHASE2","title":"Axitinib and Nivolumab for the Treatment of Mucosal Melanoma","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2022-05-17","conditions":"Mucosal Melanoma","enrollment":20},{"nctId":"NCT02224781","phase":"PHASE3","title":"Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2015-09-08","conditions":"Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma","enrollment":267},{"nctId":"NCT06581406","phase":"PHASE2, PHASE3","title":"A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma","status":"RECRUITING","sponsor":"Replimune Inc.","startDate":"2024-12-17","conditions":"Metastatic Uveal Melanoma","enrollment":280},{"nctId":"NCT05715229","phase":"PHASE2","title":"Immune Profile Selection By Fraction of ctDNA in Patients With Advanced NSCLC Treated With Immunotherapy","status":"RECRUITING","sponsor":"Hackensack Meridian Health","startDate":"2023-09-29","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":108},{"nctId":"NCT03520491","phase":"PHASE2","title":"A Study to Test the Safety of Immunotherapy With Nivolumab Alone or With Ipilimumab Before Surgery for Bladder Cancer Patients Who Are Not Suitable for Chemotherapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2018-04-25","conditions":"Bladder Cancer","enrollment":52},{"nctId":"NCT03600155","phase":"PHASE1","title":"Nivolumab and Ipilimumab After Donor Stem Cell Transplant in Treating Patients With High Risk Refractory or Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2018-10-11","conditions":"Allogeneic Hematopoietic Stem Cell Transplantation Recipient, Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia","enrollment":29},{"nctId":"NCT04606316","phase":"PHASE1","title":"Surgical Nivolumab And Ipilimumab For Recurrent GBM","status":"ACTIVE_NOT_RECRUITING","sponsor":"Patrick Wen, MD","startDate":"2021-02-01","conditions":"Glioblastoma, GBM, Glioblastoma Multiforme","enrollment":63},{"nctId":"NCT05987332","phase":"PHASE2, PHASE3","title":"IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"IDEAYA Biosciences","startDate":"2023-10-31","conditions":"Metastatic Uveal Melanoma","enrollment":420},{"nctId":"NCT03143153","phase":"PHASE3","title":"A Study to Evaluate Efficacy in Subjects With Esophageal Cancer Treated With Nivolumab and Ipilimumab or Nivolumab Combined With Fluorouracil Plus Cisplatin Versus Fluorouracil Plus Cisplatin","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2017-06-29","conditions":"Various Advanced Cancer","enrollment":970},{"nctId":"NCT05921760","phase":"PHASE1, PHASE2","title":"Ivosidenib, Nivolumab, and Ipilimumab Combination in Previously Treated Subjects With Nonresectable or Metastatic IDH1 Mutant Cholangiocarcinoma","status":"TERMINATED","sponsor":"Servier Bio-Innovation LLC","startDate":"2023-10-23","conditions":"IDH1-mutant Cholangiocarcinoma","enrollment":7},{"nctId":"NCT07403877","phase":"PHASE2","title":"Neoadjuvant Immunotherapy ± Radiotherapy in MSI-H/dMMR Locally Advanced Colorectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2026-02-01","conditions":"Colorectal Cancer (MSI-H)","enrollment":114},{"nctId":"NCT07230613","phase":"PHASE2","title":"Neo-adjuvant Immunotherapy in Patients With Localized Melanoma","status":"RECRUITING","sponsor":"UNICANCER","startDate":"2026-01-12","conditions":"Cutaneous Melanoma, Stage III, Mucosal Melanoma","enrollment":50},{"nctId":"NCT05928806","phase":"PHASE2","title":"Advanced Renal Cell Cancer Combination ImmunoThErapy Clinical Trial","status":"SUSPENDED","sponsor":"Michael B. Atkins, MD","startDate":"2023-09-25","conditions":"Advanced Renal Cell Carcinoma","enrollment":120},{"nctId":"NCT06675643","phase":"","title":"Digital Remote Monitoring of Immune Checkpoint Inhibitor Therapy Induced Toxicity Using the Vigilant App","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2024-10-14","conditions":"Malignant Skin Neoplasm, Melanoma","enrollment":100},{"nctId":"NCT04080804","phase":"PHASE2","title":"Study of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab in Head and Neck Cancer","status":"RECRUITING","sponsor":"Dan Zandberg","startDate":"2019-12-20","conditions":"Head and Neck Squamous Cell Carcinoma (HNSCC)","enrollment":80},{"nctId":"NCT05358938","phase":"EARLY_PHASE1","title":"Exercise to Boost Response to Checkpoint Blockade Immunotherapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2022-06-21","conditions":"Cutaneous Melanoma, Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma","enrollment":22},{"nctId":"NCT07394062","phase":"","title":"Real-World Comparison of Chemo-Immunotherapy Regimens in Metastatic NSCLC With PD-L1 <50% (ALCG-01)","status":"RECRUITING","sponsor":"Gazi University","startDate":"2026-02","conditions":"Nonsmall Cell Lung Cancer, Stage IV, Metastatic Nonsmall Cell Lung Cancer","enrollment":400},{"nctId":"NCT03789110","phase":"PHASE2","title":"NIMBUS: Nivolumab Plus Ipilimumab in Metastatic Hypermutated HER2-negative Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2019-03-08","conditions":"Breast Cancer","enrollment":30},{"nctId":"NCT03203473","phase":"PHASE2","title":"Study of Optimized Management of Nivolumab Based on Response in Patients With Advanced RCC (OMNIVORE Study)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Toni Choueiri, MD","startDate":"2017-10-26","conditions":"Renal Cancer","enrollment":85},{"nctId":"NCT05533697","phase":"PHASE1, PHASE2","title":"Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors","status":"RECRUITING","sponsor":"ModernaTX, Inc.","startDate":"2022-09-01","conditions":"Advanced Solid Tumors","enrollment":361},{"nctId":"NCT04938232","phase":"PHASE2","title":"Ipilimumab With or Without Nivolumab in Relapsed/Refractory cHL","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2021-06-04","conditions":"Hodgkin Lymphoma, Relapsed Hodgkin's Disease, Adult, Refractory Hodgkin Lymphoma","enrollment":13},{"nctId":"NCT07383441","phase":"PHASE3","title":"Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer","status":"NOT_YET_RECRUITING","sponsor":"SWOG Cancer Research Network","startDate":"2026-06-10","conditions":"Advanced Clear Cell Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8","enrollment":718},{"nctId":"NCT05139706","phase":"","title":"Montreal Immune-Related Adverse Events (MIRAE) Study","status":"RECRUITING","sponsor":"Sir Mortimer B. Davis - Jewish General Hospital","startDate":"2020-01-21","conditions":"Cancer, Immune System Disorder, Inflammatory Reaction","enrollment":1000},{"nctId":"NCT03340129","phase":"PHASE2","title":"Anti-PD 1 Brain Collaboration + Radiotherapy Extension (ABC-X Study)","status":"RECRUITING","sponsor":"Melanoma Institute Australia","startDate":"2019-08-14","conditions":"Melanoma Stage Iv","enrollment":218},{"nctId":"NCT06250335","phase":"PHASE2","title":"Impact of a Prebiotic Food-enriched Diet (PreFED) in Combination With Ipilimumab/Nivolumab Combination Immune Checkpoint Blockade (ICB) in ICB-refractory Melanoma Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2024-03-01","conditions":"ICB-refractory Melanoma","enrollment":4},{"nctId":"NCT04562129","phase":"PHASE2","title":"IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients","status":"RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2020-09-24","conditions":"Melanoma Stage III, Melanoma Stage IV, Inoperable Disease","enrollment":29}],"_emaApprovals":[],"_faersSignals":[],"crossReferences":{"chemblId":"CHEMBL1789844"},"_approvalHistory":[],"publicationCount":740,"_revenueScrapedAt":"2026-04-01 10:46:55.139243+00","rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Nivolumab and Ipilimumab","genericName":"nivolumab-and-ipilimumab","companyName":"Pfizer Inc.","companyId":"pfizer","modality":"Monoclonal antibody","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":7,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":5,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:49:49.023726+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}